Patient-Derived Xenograft / PDX Model Market by Type (Mice, Rat), Implantation Method (Subcutaneous, Orthotopic), Tumor Type (Respiratory, Hematological), Application (Drug Development, Biobanks), End User (Pharma, Biotech, CROs) - Global Forecast to 2028
The global PDX model market in terms of revenue was estimated to be worth $366 million in 2023 and is poised to reach $687 million by 2028, growing at a CAGR of 13.4% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The key factors driving the growth of the global patient-derived xenografts model market are the growing demand for personalized medicine, technological advancements in PDX technology, and rising investments in cancer research. However, the FDA’s announcement to discontinue animal models for clinical trials is expected to restrain market growth to a certain extent.
Attractive Opportunities in the patient-derived xenografts/ PDX models market
To know about the assumptions considered for the study, Request for Free Sample Report
PDX Model Market Dynamics
DRIVER: Growing demand for personalized medicine
Personalized medicine aims to tailor medical treatments to individual patients based on their unique genetic and molecular profiles, enhancing treatment efficacy and minimizing adverse effects. PDX models have emerged as pivotal tools in this paradigm shift, providing a bridge between preclinical research and clinical application. PDX models allow researchers to replicate patient-specific tumors in an in vivo context, enabling the testing of various therapies for personalized treatment strategies. Their ability to maintain the heterogeneity and microenvironment of tumors closely mimics real-world patient scenarios. As a result, pharmaceutical companies and research institutions are increasingly adopting PDX models to develop and validate personalized treatment approaches.
RESTRAINT: FDA’s announcement to discontinue animal models for clinical trials
In December 2022, USFDA announced the dispensing of the prerequisite for animal testing in the initial phases of pharmaceutical development, marking a pivotal juncture in the regulatory framework governing drug research and innovation. This strategic shift stems from an amplified acknowledgment of the inherent limitations inherent in conventional animal models and the overarching drive to contemporize drug development paradigms. Although this shift is poised to herald constructive changes within the industry, it also holds the potential to engender certain challenges, particularly within the domain of the patient-derived xenograft (PDX) model market.
OPPORTUNITY: Emergence of CRISPR in biomedical research
CRISPR tool enables precise and efficient genetic modifications in PDX models, allowing researchers to create more accurate and sophisticated models that closely mimic human disease conditions. CRISPR-mediated modifications enable the introduction of specific mutations, deletions, or insertions into PDX models, replicating patient-specific genetic alterations observed in various diseases, including cancer. This capability not only enhances the authenticity of PDX models but also facilitates the investigation of genetic drivers and disease mechanisms. By utilizing CRISPR-edited PDX models, researchers can better dissect the role of specific genes and pathways in tumor growth, progression, and treatment responses, thereby providing valuable insights into personalized therapeutic strategies.
CHALLENGE: Development of alternative animal testing methods
Alternative methods, like in vitro cell culture models, organoids, and microphysiological systems, offer advantages such as reduced animal usage, cost-effectiveness, and high-throughput capabilities. This trend aligns with increasing ethical and regulatory concerns regarding traditional animal testing. As the pharmaceutical and research industries pivot toward more humane and predictive models, the adoption of these alternatives poses a potential threat to the demand for PDX models. Additionally, these alternatives offer faster results, allowing for quicker decision-making in drug development pipelines. This dynamic landscape necessitates strategic adaptations by PDX model providers to maintain their market relevance.
Patient Derived Xenograft / PDX Model Market Ecosystem:
Prominent companies in the market include well-established, financially stable manufacturers of patient-derived xenografts/ PDX model products. These companies have been operating in the market for several years and possess diversified, state-of-the-art technologies, product portfolios, and strong global sales and marketing networks. Prominent companies in this market include JSR Corporation (Japan), Wuxi Apptec (China), The Jackson Laboratory (US), Charles River Laboratories International, Inc. (US), Taconic Biosciences, Inc. (US), Oncodesign Precision Medicine (France), Inotiv, Inc. (US), Pharmatest Services (Finland), Hera BioLabs (US), EPO Berlin-Buch GmbH (Germany), Xentech (France), Urosphere (France), Altogen Labs (US), Abnova Corporation (US), Genesis Biotechnology Group (US), Biocytogen Pharmaceuticals Co., Ltd. (China), Creative Animodel (US), BioDuro-Sundia (US), Aragen Life Sciences (India), Shanghai LIDE Biotech Co., Ltd. (China), Certis Oncology Solutions (US), InnoSer (Netherlands), IVRS AB (Sweden), Beijing IDMO Co. Ltd. (China), and Shanghai Chempartner Co. Ltd. (China).
The subcutaneous segment accounted for the largest share of the implantation method segment in the PDX Model Industry in 2023.
Based on implantation methods, the PDX model market is categorized into subcutaneous implantation, orthotopic implantation, and other implantation methods. In 2023, the subcutaneous segment accounted for the largest share and the fastest-growing segment of the patient-derived xenografts/ PDX models market. The major drivers are propelling the accessibility and ease of Implantation of the subcutaneous method and the cost and time efficiency of the method.
The pharmaceutical and biotechnology companies segment dominated the end-user segment in the PDX model industry in 2023.
Based on the end user, the segment of the PDX model market is categorized into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. In 2023, the pharmaceutical and biotechnology companies segment dominated the end-user segment with the highest revenue share. Collaborative projects amongst the pharmaceutical and biotechnology companies, rising numbers of drugs in the R&D pipeline, and increasing investment in R&D are propelling the growth of the pharmaceutical and biotechnology companies market.
North America was the largest market for PDX model industry in 2023.
Geographically, the PDX model market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East Africa. The patient-derived xenografts/ PDX models market is dominated by North America in 2023, and this dominance is anticipated to continue throughout the forecast period. Factors such as extensive research focusing on novel oncology therapies, a rise in cancer prevalence, and increased adoption of personalized medicine are driving the growth of the market in North America.
To know about the assumptions considered for the study, download the pdf brochure
The prominent players in the PDX model market are JSR Corporation (Japan), Wuxi Apptec (China), The Jackson Laboratory (US), Charles River Laboratories International, Inc. (US), Taconic Biosciences, Inc. (US), Oncodesign Precision Medicine (France), Inotiv, Inc. (US), Pharmatest Services (Finland), Hera BioLabs (US), EPO Berlin-Buch GmbH (Germany), Xentech (France), Urosphere (France), Altogen Labs (US), Abnova Corporation (US), Genesis Biotechnology Group (US), Biocytogen Pharmaceuticals Co., Ltd. (China), Creative Animodel (US), BioDuro-Sundia (US), Aragen Life Sciences (India), Shanghai LIDE Biotech Co., Ltd. (China), Certis Oncology Solutions (US), InnoSer (Netherlands), IVRS AB (Sweden), Beijing IDMO Co. Ltd. (China), and Shanghai Chempartner Co. Ltd. (China).
Scope of the PDX Model Industry
|
Report Metric |
Details |
|
Market Revenue in 2023 |
$366 million |
|
Estimated Value by 2028 |
$687 million |
|
Revenue Rate |
Poised to grow at a CAGR of 13.4% |
|
Market Driver |
Growing demand for personalized medicine |
|
Market Opportunity |
Emergence of CRISPR in biomedical research |
This report categorizes the PDX model market to forecast revenue and analyze trends in each of the following submarkets:
By type
- Mouse Model
- Rat Model
By Implantation Method
- Subcutaneous implantation
- Orthotopic implantation
- Other implantation methods
By Tumor Type
- Gastrointestinal tumor models
- Gynecological tumor models
- Respiratory tumor models
- Urological tumor models
- Hematological tumor models
- Other tumor models
By Application
- Preclinical drug development
- Biomarker analysis
- Translational research
- Biobanking
By End Users
- Pharmaceutical & biotechnology companies
- Contract research organizations (CROs)
- Academic & research institutions
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
-
Asia Pacific (APAC)
- Japan
- India
- China
- Australia
- South Korea
- Rest of Asia Pacific (RoAPAC)
-
Latin America
- Brazil
- Rest of Latin America
-
Middle East Africa
- Middle East
- Africa
Recent Developments in PDX Model Industry
- In December 2022, Crown Bioscience, Inc., a subsidiary of JSR Life Sciences, entered into a worldwide licensing agreement with ERS Genomics Limited. This agreement granted Crown Bioscience complete global access to ERS's foundational CRISPR/Cas9 patent portfolio, enabling the company to utilize CRISPR/Cas9 for genetic editing on a global scale. Under the provisions of this agreement, Crown Bioscience broadened its capabilities in genetic manipulation. The company is exploring the potential of gene editing within three-dimensional models of patient-derived tumor organoids.
- In July 2022, GemPharmatech entered into a strategic licensing arrangement with Charles River Laboratories, Inc. This partnership entails the exclusive distribution rights for GemPharmatech's advanced NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines within the North American region.
- In November 2021, Inotiv announced the completion of the acquisition of Envigo RMS Holding Corp., a leading global provider of research models and services.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global PDX model market?
The global PDX model market boasts a total revenue value of $687 million by 2028.
What is the estimated growth rate (CAGR) of the global PDX model market?
The global PDX model market has an estimated compound annual growth rate (CAGR) of 13.4% and a revenue size in the region of $366 million in 2023.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 20)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED IN THE REPORT
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 24)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
FIGURE 3 PDX MODEL MARKET: BREAKDOWN OF PRIMARIES
2.1.2.1 Key industry insights
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 – REVENUE SHARE ANALYSIS, 2020
FIGURE 5 AVERAGE MARKET SIZE ESTIMATION, 2020
FIGURE 6 MARKET: CAGR PROJECTIONS, 2021–2026
FIGURE 7 MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
2.5 RISK ANALYSIS
3 EXECUTIVE SUMMARY (Page No. - 34)
FIGURE 9 PDX MODEL MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 10 MARKET, BY TUMOR TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 11 MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 12 MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 13 MARKET: GEOGRAPHIC SNAPSHOT
4 PREMIUM INSIGHTS (Page No. - 38)
4.1 PDX MODEL MARKET OVERVIEW
FIGURE 14 INCREASING SUPPORT FOR CANCER RESEARCH FROM PUBLIC AND PRIVATE SECTORS AND GROWING DEMAND FOR PRECISION MEDICINE ARE KEY GROWTH DRIVERS
4.2 NORTH AMERICA: MARKET, MARKET SHARE (2020)
FIGURE 15 MICE MODELS COMMANDED THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2020
4.3 MARKET SHARE, BY END USER (2020)
FIGURE 16 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES COMMANDED THE LARGEST SHARE OF THE MARKET IN 2020
4.4 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 17 CHINA TO WITNESS THE HIGHEST GROWTH IN THE MARKET DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 41)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 PDX MODEL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 PDX MODEL INDUSTRY: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Growing demand for personalized medicine
5.2.1.2 Continuous support for cancer research from the public & private sectors
5.2.1.3 Rising pharma R&D
5.2.2 RESTRAINTS
5.2.2.1 High cost of personalized PDX models
5.2.2.2 Stringent guidelines for the use of animal models in cancer research
5.2.3 OPPORTUNITIES
5.2.3.1 Rising demand for humanized PDX models
5.2.4 CHALLENGES
5.2.4.1 Limitations of PDX models
5.3 IMPACT OF THE COVID-19 OUTBREAK ON THE GROWTH OF THE MARKET
5.4 TECHNOLOGICAL ANALYSIS
5.5 PRICING ANALYSIS
5.6 VALUE CHAIN ANALYSIS
FIGURE 19 VALUE CHAIN ANALYSIS OF MARKET: R&D AND MANUFACTURING PHASES ADD MAXIMUM VALUE
FIGURE 20 VALUE CHAIN: CREATION OF PDX MODELS—MAXIMUM VALUE IS ADDED DURING THE IMPLANTATIONS OF TUMOR CELLS IN IMMUNODEFICIENT MICE OR RATS
5.7 ECOSYSTEM ANALYSIS OF THE MARKET
FIGURE 21 ECOSYSTEM ANALYSIS OF THE MARKET
TABLE 2 SUPPLY CHAIN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 3 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 REGULATORY ANALYSIS
5.9.1 NORTH AMERICA
5.9.2 EUROPE
5.9.3 ASIA PACIFIC
5.9.3.1 China
5.9.3.2 Japan
5.9.3.3 India
5.9.3.4 Australia
5.9.4 LATIN AMERICA
5.9.5 MIDDLE EAST & AFRICA
5.10 PATENT ANALYSIS
FIGURE 22 PATENTS GRANTED FOR PDX MODELS, JANUARY 2010–DECEMBER 2020
6 PDX MODEL MARKET, BY TYPE (Page No. - 59)
6.1 INTRODUCTION
TABLE 4 PDX MODEL INDUSTRY, BY TYPE, 2019–2026 (USD MILLION)
6.2 MICE MODELS
6.2.1 EASE OF PROCUREMENT AND WIDE AVAILABILITY OF MICE MODELS DRIVE THE GROWTH OF THIS SEGMENT
TABLE 5 PDX MICE MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 6 NORTH AMERICA: PDX MICE MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 7 EUROPE: PDX MICE MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 8 ASIA PACIFIC: PDX MICE MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3 RAT MODELS
6.3.1 FACTORS SUCH AS EASIER SURGICAL MANIPULATION AND LARGER TUMOR SIZE WILL SUPPORT USE OF RAT MODELS
TABLE 9 PDX RAT MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 10 NORTH AMERICA: PDX RAT MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 11 EUROPE: PDX RAT MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 12 ASIA PACIFIC: PDX RAT MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7 PDX MODEL MARKET, BY TUMOR TYPE (Page No. - 64)
7.1 INTRODUCTION
TABLE 13 PDX MODEL INDUSTRY, BY TUMOR TYPE, 2019–2026 (USD MILLION)
7.2 GASTROINTESTINAL TUMOR MODELS
7.2.1 NEWLY DEVELOPED GASTROINTESTINAL TUMOR MODELS MIMIC THE TUMOR BETTER THAN PREVIOUS MODELS
TABLE 14 GASTROINTESTINAL TUMOR MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 15 NORTH AMERICA: GASTROINTESTINAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 16 EUROPE: GASTROINTESTINAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 17 ASIA PACIFIC: GASTROINTESTINAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3 GYNECOLOGICAL TUMOR MODELS
7.3.1 HIGH INCIDENCE OF TARGET CANCERS HAS DRIVEN DEMAND FOR TUMOR MODELS
TABLE 18 GYNECOLOGICAL TUMOR MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 19 NORTH AMERICA: GYNECOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 20 EUROPE: GYNECOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 21 ASIA PACIFIC: GYNECOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.4 RESPIRATORY TUMOR MODELS
7.4.1 RISING PREVALENCE OF LUNG CANCER TO DRIVE MARKET GROWTH
TABLE 22 RESPIRATORY TUMOR MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 23 NORTH AMERICA: RESPIRATORY TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 24 EUROPE: RESPIRATORY TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 25 ASIA PACIFIC: RESPIRATORY TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.5 UROLOGICAL TUMOR MODELS
7.5.1 COMPANIES ARE FOCUSING ON EXPANDING THEIR PORTFOLIO FOR UROLOGICAL CANCERS
TABLE 26 UROLOGICAL TUMOR MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 27 NORTH AMERICA: UROLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 28 EUROPE: UROLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 29 ASIA PACIFIC: UROLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.6 HEMATOLOGICAL TUMOR MODELS
7.6.1 NEW STRAINS SUCH AS NSG AND NOG HAVE INCREASED THE LIFE SPAN OF HEMATOLOGICAL TUMOR MODELS
TABLE 30 HEMATOLOGICAL TUMOR MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 31 NORTH AMERICA: HEMATOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 32 EUROPE: HEMATOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 33 ASIA PACIFIC: HEMATOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.7 OTHER TUMOR MODELS
TABLE 34 OTHER TUMOR MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 35 NORTH AMERICA: OTHER TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 36 EUROPE: OTHER TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 37 ASIA PACIFIC: OTHER TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8 PDX MODEL MARKET, BY APPLICATION (Page No. - 76)
8.1 INTRODUCTION
TABLE 38 PDX MODEL INDUSTRY, BY APPLICATION, 2021–2026 (USD MILLION)
8.2 PRECLINICAL DRUG DEVELOPMENT
8.2.1 RISE IN NUMBER OF CLINICAL TRIALS WILL DRIVE THE GROWTH OF THIS SEGMENT
TABLE 39 MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY REGION, 2019–2026 (USD MILLION)
TABLE 40 NORTH AMERICA: MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 41 EUROPE: MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 42 ASIA PACIFIC: MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
8.3 BIOMARKER ANALYSIS
8.3.1 GROWING INTEREST IN PRECISION MEDICINE WILL CONTRIBUTE TO THE DEMAND FOR PDX MODELS FOR BIOMARKER ANALYSIS
TABLE 43 MARKET FOR BIOMARKER ANALYSIS, BY REGION, 2019–2026 (USD MILLION)
TABLE 44 NORTH AMERICA: MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 45 EUROPE: MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 46 ASIA PACIFIC: MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2019–2026 (USD MILLION)
8.4 BASIC CANCER RESEARCH
8.4.1 RISING FUNDING FOR CANCER RESEARCH WILL DRIVE MARKET GROWTH IN THIS SEGMENT
TABLE 47 MARKET FOR BASIC CANCER RESEARCH, BY REGION, 2019–2026 (USD MILLION)
TABLE 48 NORTH AMERICA: MARKET FOR BASIC CANCER RESEARCH, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 49 EUROPE: MARKET FOR BASIC CANCER RESEARCH, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 50 ASIA PACIFIC: MARKET FOR BASIC CANCER RESEARCH, BY COUNTRY, 2019–2026 (USD MILLION)
9 PDX MODEL MARKET, BY END USER (Page No. - 84)
9.1 INTRODUCTION
TABLE 51 PDX MODEL INDUSTRY, BY END USER, 2019–2026 (USD MILLION)
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 RISING COLLABORATION BETWEEN PHARMA & BIOTECH COMPANIES FOR DEVELOPING CANCER THERAPEUTICS
TABLE 52 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 53 NORTH AMERICA: MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 54 EUROPE: MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 55 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
9.3 CONTRACT RESEARCH ORGANIZATIONS
9.3.1 RISING OUTSOURCING OF DRUG DISCOVERY SERVICES WILL DRIVE MARKET GROWTH
TABLE 56 MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 57 NORTH AMERICA: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 58 EUROPE: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 59 ASIA PACIFIC: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
9.4 ACADEMIC & RESEARCH INSTITUTIONS
9.4.1 INCREASE IN GOVERNMENT LIFE SCIENCES R&D EXPENDITURE WILL CONTRIBUTE TO THE GROWTH OF THIS SEGMENT
TABLE 60 MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 61 NORTH AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 62 EUROPE: MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 63 ASIA PACIFIC: MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2019–2026 (USD MILLION)
10 PDX MODEL MARKET, BY REGION (Page No. - 92)
10.2 NORTH AMERICA
TABLE 64 PDX MODEL INDUSTRY, BY REGION, 2019–2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 23 NORTH AMERICA: PDX MODEL MARKET SNAPSHOT
TABLE 65 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 66 NORTH AMERICA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 67 NORTH AMERICA: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 68 NORTH AMERICA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 69 NORTH AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.1 US
10.2.1.1 Growing focus on cancer research in the US will drive market growth
TABLE 70 US: PDX MODEL MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 71 US: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 72 US: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 73 US: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Growth in Canada can be attributed to rising funding for stem cell research in the country
TABLE 74 CANADA: PDX MODEL MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 75 CANADA: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 76 CANADA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 77 CANADA: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3 EUROPE
TABLE 78 EUROPE: PDX MODEL MARKET, BY COUNTRY/REGION, 2019–2026 (USD MILLION)
TABLE 79 EUROPE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 80 EUROPE: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 81 EUROPE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 82 EUROPE: PDX MODEL INDUSTRY, BY END USER, 2019–2026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Government funding for life science R&D and basic cancer research will drive market growth
TABLE 83 GERMANY: PDX MODEL MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 84 GERMANY: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 85 GERMANY: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 86 GERMANY: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.2 UK
10.3.2.1 The rising incidence of cancer cases will lead to an increase in cancer research, which will drive market growth
TABLE 87 UK: PDX MODEL MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 88 UK: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 89 UK: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 90 UK: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Increasing government funding for cancer research
TABLE 91 FRANCE: PDX MODEL MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 92 FRANCE: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 93 FRANCE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 94 FRANCE: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.4 ROE
TABLE 95 ROE: PDX MODEL MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 96 ROE: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 97 ROE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 98 ROE: PDX MODEL INDUSTRY, BY END USER, 2019–2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 24 ASIA PACIFIC: PDX MODEL MARKET SNAPSHOT
TABLE 99 ASIA PACIFIC: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 100 ASIA PACIFIC: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 101 ASIA PACIFIC: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 102 ASIA PACIFIC: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 103 ASIA PACIFIC: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.1 CHINA
10.4.1.1 The growing pharmaceutical industry and rising number of CROs in the country will drive market growth
TABLE 104 CHINA: PDX MODEL MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 105 CHINA: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 106 CHINA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 107 CHINA: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Research collaborations and growing geriatric population—key growth drivers in Japan
TABLE 108 JAPAN: PDX MODEL MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 109 JAPAN: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 110 JAPAN: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 111 JAPAN: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.3 REST OF ASIA PACIFIC
TABLE 112 ROAPAC: PDX MODEL MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 113 ROAPAC: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 114 ROAPAC: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 115 ROAPAC: PDX MODEL INDUSTRY, BY END USER, 2019–2026 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 RISING PHARMACEUTICAL R&D EXPENDITURE IN THE REGION WILL DRIVE THE GROWTH OF THE MARKET
TABLE 116 LATIN AMERICA: PDX MODEL MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 117 LATIN AMERICA: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 118 LATIN AMERICA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 119 LATIN AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 MARKET GROWTH DRIVEN BY CHANGING DEMOGRAPHICS AND FAVORABLE POLICIES FOR PHARMA R&D
TABLE 120 MIDDLE EAST AND AFRICA: PDX MODEL MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 121 MIDDLE EAST AND AFRICA: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 122 MIDDLE EAST AND AFRICA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 123 MIDDLE EAST AND AFRICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 122)
11.1 OVERVIEW
11.2 MARKET EVALUATION FRAMEWORK
TABLE 124 MARKET EVALUATION FRAMEWORK: PARTNERSHIPS, AGREEMENTS, JOINT VENTURES, AND COLLABORATIONS—THE MAJOR STRATEGIES ADOPTED BY PLAYERS
11.3 MARKET SHARE ANALYSIS
FIGURE 25 PDX MODEL MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 26 TOP MARKET PLAYERS DOMINATE THE PDX MODEL INDUSTRY
11.5 COMPANY EVALUATION QUADRANT
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE
11.5.4 EMERGING COMPANIES
FIGURE 27 MARKET: COMPANY EVALUATION QUADRANT, 2020
11.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 28 MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
11.7 COMPANY PRODUCT FOOTPRINT
TABLE 125 PRODUCT PORTFOLIO ANALYSIS: MARKET (2020)
11.8 COMPANY GEOGRAPHIC FOOTPRINT
TABLE 126 GEOGRAPHIC REVENUE MIX: MARKET (2020)
11.9 COMPETITIVE SCENARIO
11.9.1 MARKET: PRODUCT & SERVICE LAUNCHES, JANUARY 2018–FEBRUARY 2021
11.9.2 PDX MODEL INDUSTRY: DEALS, JANUARY 2019–FEBRUARY 2021
11.9.3 PDX MODEL MARKET: OTHER DEVELOPMENTS, JANUARY 2018–FEBRUARY 2021
12 COMPANY PROFILES (Page No. - 133)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
12.1 KEY MARKET PLAYERS
12.1.1 JSR CORPORATION
FIGURE 29 JSR CORPORATION: COMPANY SNAPSHOT (2019)
12.1.2 WUXI APPTEC
FIGURE 30 WUXI APPTEC: COMPANY SNAPSHOT (2020)
12.1.3 THE JACKSON LABORATORY
FIGURE 31 THE JACKSON LABORATORY: COMPANY SNAPSHOT (2019)
12.1.4 CHARLES RIVER LABORATORIES
FIGURE 32 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2020)
12.1.5 CHAMPIONS ONCOLOGY
FIGURE 33 CHAMPIONS ONCOLOGY: COMPANY SNAPSHOT (2020)
12.1.6 ONCODESIGN
FIGURE 34 ONCODESIGN: COMPANY SNAPSHOT (2020)
12.1.7 ENVIGO
12.1.8 PHARMATEST SERVICES
12.1.9 HERA BIOLABS
12.1.10 EPO BERLIN-BUCH GMBH
12.1.11 XENTECH
12.1.12 UROSPHERE
12.2 OTHER PLAYERS
12.2.1 ABNOVA CORPORATION
12.2.2 GENESIS BIOTECHNOLOGY GROUP
12.2.3 EXPLORA BIOLABS
12.2.4 BIOCYTOGEN
12.2.5 LIVING TUMOR LABORATORY
12.2.6 BIODURO
12.2.7 ARAGEN LIFE SCIENCES W.E.F
12.2.8 SHANGHAI LIDE BIOTECH
*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 166)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the patient-derived xenograft/ PDX model market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the patient-derived xenograft/ PDX model market. The secondary sources used for this study include some of the key secondary sources: American Association for Cancer Research, American Association for Laboratory Animal Science, EurOPDX, European Animal Research Association, European Society for Medical Oncology, European Association for Cancer Research, Federation for Laboratory Animal Science Associations, Medical Research Council, Sao Paulo Research Foundation, Centers for Disease Control and Prevention, Food and Drug Administration, Company Websites, Annual Reports, SEC Filings, Press Releases, Investor Presentations, Interviews with Experts, and MarketsandMarkets Analysis. Secondary sources include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements), business magazines and research journals, press releases, and trade, business, and professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess the prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the patient-derived xenograft/ PDX model market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive secondary research
- The revenues generated from the patient-derived xenograft/ PDX model business of leading players have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Global patient-derived xenograft/ PDX model Market: Bottom-Up Approach
To know about the assumptions considered for the study, Request for Free Sample Report
Global patient-derived xenograft/ PDX model Market Size: Top-Down Approach
Data Triangulation
After arriving at the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Patient-derived xenograft (PDX) models are models in which tumor tissues from patients are implanted into immunodeficient mice and rats and have shown superiority in recapitulating the characteristics of cancer, such as the spatial structure of cancer and the intratumor heterogeneity of cancer. Moreover, PDX models retain the genomic features of patients across different stages, subtypes, and diversified treatment backgrounds. The market is driven by the increasing demand for oncology research and precision medicine.
Key Stakeholders
- Manufacturers and distributors of patient-derived xenograft/ PDX models
- Pharmaceutical and biotechnology companies
- Market research and consulting firms
- R&D centers
- Researchers and scientists
- Academic & research institutes
Report Objectives
- To define, describe, and forecast the patient-derived xenograft/ PDX model market based on type, implantation method, tumor type, application, and end user.
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, opportunities, and trends)
- To strategically analyze micro markets with respect to individual growth trends, future prospects, and contributions to the overall patient-derived xenograft/ PDX model market.
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the patient-derived xenograft/ PDX model market.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Company Information
- Twenty-five company profiles
Generating Response ...
Growth opportunities and latent adjacency in Patient-Derived Xenograft / PDX Model Market